Literature DB >> 20450431

Somatostatin receptor 2 expression determined by immunohistochemistry in cold thyroid nodules exceeds that of hot thyroid nodules, papillary thyroid carcinoma, and Graves' disease.

Seda Sancak1, Anna Hardt, Joerg Singer, Guenther Klöppel, Funda Tanay Eren, Bahadir M Güllüoglu, Leyla Semiha Sen, Zeynep Sever, Nefise Sema Akalin, Markus Eszlinger, Ralf Paschke.   

Abstract

BACKGROUND: There is a plethora of partly contradictory reports on somatostatin receptor (SSTR) expression in thyroid tumors. Therefore, our goal was to systematically determine SSTR2 expression in benign cold thyroid nodules (CNs), hot thyroid nodules (HNs), papillary carcinomas (PCs), and Graves' disease (GD) in comparison with intraindividual control tissues by means of immunohistochemistry.
METHODS: Tissue sections from 19 HNs, 10 CNs, 17 PCs and their surrounding tissues, and 8 GD thyroids were immunostained for SSTR2. Membranous SSTR2 staining was quantitated by evaluating 10 high-power fields (HPFs) systematically distributed along the largest diameter of the tissue section.
RESULTS: The area covered by thyroid epithelial cells in 10 HPFs expressed as median (in mm(2)) was 0.53 for CNs, 0.44 for HNs, 1.5 for PCs, 1.3 for GD, and 0.3 for the surrounding tissues. The SSTR2 staining density determined by dividing the area of SSTR2 positively stained thyroid epithelial cells (in mm(2)) by the area of all thyroid epithelial cells (in mm(2)) in 10 HPFs was 0.1662 for CNs, 0.0204 for HNs, 0.0369 for PCs, and 0.0386 for GD.
CONCLUSIONS: SSTR2 expression is inhomogeneous in thyroid disease, with the highest density detected in CNs. It remains to be determined whether this finding could be of pathophysiologic or therapeutic relevance. The high SSTR2 density in CNs should be considered in the interpretation of SSTR scintigraphy-positive findings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20450431     DOI: 10.1089/thy.2009.0203

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  2 in total

1.  Prospective evaluation of (68)Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative (131)I-whole body scan: comparison with (18)F-FDG PET-CT.

Authors:  Parveen Kundu; Sneh Lata; Punit Sharma; Harmandeep Singh; Arun Malhotra; Chandrasekhar Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

Review 2.  Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer.

Authors:  Zhuan-Zhuan Mu; Xin Zhang; Yan-Song Lin
Journal:  Chonnam Med J       Date:  2019-09-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.